

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**丽珠医药**  
**LIVZON**

**麗珠醫藥集團股份有限公司**

**LIVZON PHARMACEUTICAL GROUP INC.\***

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1513)**

**POLL RESULTS OF  
THE 2024 FIRST EXTRAORDINARY GENERAL MEETING  
HELD ON 12 JANUARY 2024**

Reference is made to the circular of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.\* (the “**Company**”) dated 19 December 2023 (the “**Circular**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The board of directors (the “**Board**”) of the Company hereby announces that the 2024 First Extraordinary General Meeting (the “**EGM**” or “**Meeting**”) was held on 12 January 2024 at the Conference Room on the 6th Floor of Headquarters Building, 38 Chuangye North Road, Jinwan District, Zhuhai, Guangdong Province, China, and all the proposed resolutions as set out in the notice of the Meeting were duly passed by the Shareholders of the Company by way of poll.

Details of the resolutions considered at the Meeting were set out in the Circular.

As at the record date of the EGM (i.e., 5 January 2024), the total number of issued shares of the Company was 924,473,857 shares (the “**Shares**”) (comprising 614,642,640 A Shares and 309,831,217 H Shares), representing the total number of Shares entitling the holders (or the authorized proxies) to attend and vote on the resolutions proposed at the EGM.

To the best of the Directors’ knowledge, information and belief and having made all reasonable enquiries, there were no Shares of the Company (i) entitling the holders to, pursuant to Rule 13.40 of the Hong Kong Listing Rules, attend and abstain from voting in favour of; or (ii) of which the holders are required under the Hong Kong Listing Rules to abstain from voting on the resolutions proposed at the EGM and none of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the EGM.

## ATTENDANCE OF THE EGM

Set out below are the details of the Shareholders and authorized proxies present at the EGM:

<b>Number of Shareholders and authorized proxies</b>	<b>72</b>
Including: Number of A Shareholders and authorized proxies	71
Number of H Shareholders and authorized proxies	1
<b>Total number of Shares carrying voting rights (shares)</b>	<b>482,701,117</b>
Including: Total number of A Shares of the Company carrying voting rights held by A Shareholders and authorized proxies (shares)	282,274,876
Total number of H Shares of the Company carrying voting rights held by H Shareholders and authorized proxies (shares)	200,426,241
<b>Percentage of the total number of Shares of the Company carrying voting rights (%)</b>	<b>52.21%</b>
Including: Total number of shares carrying voting rights held by A Shareholders and authorized proxies as a percentage of the total number of Shares of the Company (%)	30.53%
Total number of shares carrying voting rights held by H Shareholders and authorized proxies as a percentage of the total number of Shares of the Company (%)	21.68%

## POLL RESULTS OF THE EGM - SEPCIAL RESOLUTIONS

The table below sets out the poll results in respect of the resolutions proposed at the EGM:

No	Resolutions	Class of Shares	Number of Shares with voting rights held by Shareholders present at the meeting	For		Against		Abstain	
				Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting	Number of Shares	Percentage (%) of number of Shares with voting rights held by Shareholders present at the meeting
<b>Special Resolutions</b>									
1	To consider and approve the termination of the proposed spin-off and listing of a controlling subsidiary of the Company on the ChiNext Board.	Total	482,701,117	482,501,017	99.9585%	23,900	0.0050%	176,200	0.0365%
		A Shares	282,274,876	282,250,976	99.9915%	23,900	0.0085%	0	0.0000%
		H Shares	200,426,241	200,250,041	99.9121%	0	0.0000%	176,200	0.0879%
2	To consider and approve the application for listing of Livzon Diagnostics, a controlling subsidiary of the Company, on the NEEQ.	Total	482,701,117	482,505,017	99.9594%	19,900	0.0041%	176,200	0.0365%
		A Shares	282,274,876	282,254,976	99.9930%	19,900	0.0070%	0	0.0000%
		H Shares	200,426,241	200,250,041	99.9121%	0	0.0000%	176,200	0.0879%
3	To consider and approve the authorization granted by the general meeting to the Board and its authorized persons to deal with matters relating to the listing of Livzon Diagnostics on the NEEQ.	Total	482,701,117	482,505,017	99.9594%	19,900	0.0041%	176,200	0.0365%
		A Shares	282,274,876	282,254,976	99.9930%	19,900	0.0070%	0	0.0000%
		H Shares	200,426,241	200,250,041	99.9121%	0	0.0000%	176,200	0.0879%
As votes cast for the above special resolutions were more than two-thirds of the valid voting rights of Shareholders (including authorized proxies) present at the EGM, the above resolutions were duly passed as special resolutions at the EGM.									

Grant Thornton (Special General Partnership) acted as the scrutineer for the vote-taking at the Meetings. The Company's PRC legal advisor, D&S Law Firm (廣東德賽律師事務所), two representatives of Shareholders and a representative of supervisors of the Company also jointly acted as the scrutineers for the vote-taking of the poll at the Meeting.

### **LEGAL OPINION ISSUED BY LAWYERS**

Delegated lawyers from D&S Law Firm witnessed the Meetings and issued the "Legal Opinions of D&S Law Firm on EGM of Livzon Pharmaceutical Group Inc. (《廣東德賽律師事務所關於麗珠醫藥集團股份有限公司2024年第一次臨時股東大會的法律意見書》)", certifying that: "The convening and procedures of the Meeting comply with the requirements of laws, regulations and Articles of Association, the qualifications of personnels who attended the Meeting, the qualifications of the conveners and the voting procedures of the Meeting are legal and effective, and the voting results of the resolutions at the Meeting are legal and effective."

### **SPECIAL NOTICE**

No resolutions were rejected at the Meeting and no resolutions adopted in previous general meetings were amended at the Meeting.

### **ATTENDANCE RECORD OF THE DIRECTORS**

Except for Mr. Zhu Baoguo, Mr. Xu Guoxiang and Mr. Yu Xiong who did not attend the EGM due to other business commitment, all other Directors have attended the Meeting either in person or through electronic means.

By order of the Board  
麗珠醫藥集團股份有限公司  
**Livzon Pharmaceutical Group Inc.** \*  
**Yang Liang**  
Company Secretary

Zhuhai, China  
12 January 2024

*As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.*

*\* For identification purpose only*